Korro Bio, Inc. announced it has submitted an application to the Australian Alfred Health Human Ethics Committee to begin a first-in-human Phase 1/2 clinical trial for its drug candidate, KRRO-121. The trial is for the potential treatment of hyperammonemia in patients with Urea Cycle Disorders (UCDs).
Key Details
- Drug Candidate: KRRO-121, a GalNAc-conjugated RNA editing oligonucleotide.
- Trial Phase & Purpose: The Phase 1/2 trial will evaluate the safety, tolerability, and pharmacokinetics of escalating doses in healthy volunteers and patients with UCDs.
- Regulatory Action: The submission was filed on August 19, 2026, to the Australian ethics committee to receive approval to commence the study.